ArticlePrenatal diagnosis2026
Reproductive Decision-Making Among BRCA1/2 Pathogenic Variants Carriers and Physicians: Attitudes Toward Preimplantation and Prenatal Genetic Testing.
Article in Prenatal diagnosis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fertility desires and outcomes in patients with selected hereditary cancer syndromes.Gynecologic oncology reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective of this paper is to investigate the knowledge and attitudes of BRCA1/2 pathogenic variant carriers and gynecologists regarding preimplantation genetic tests for monogenic diseases (PGT-M) and prenatal diagnosis (PND).
methodsA survey using structured questionnaires was completed by 89 BRCA1/2 carriers and 37 gynecologists, assessing awareness, attitudes, and ethical concerns.
resultsBefore receiving information, only 28% of carriers were aware of PGT-Mand PND. Once informed, the majority believed that these options should be discussed with all BRCA mutation carriers as part of standard reproductive counseling (87.6% for PGT-M and 85.7% for PND). Many indicated a willingness to consider their use. Nonetheless, concerns remained, particularly regarding hormonal stimulation, pregnancy termination, and ethical implications. Among gynecologists, awareness of PGT-M and PND as options for BRCA carriers was inconsistent (45.9% and 51.4%, respectively), and few routinely discussed these options with patients. Ethical concerns were common, and 86.5% of clinicians expressed the need for clearer guidelines and multidisciplinary collaboration.
conclusionThe findings reveal a discrepancy between reproductive preferences of BRCA mutation carriers and current practices and knowledge among healthcare professionals. Bridging this gap will require educational efforts, development of guidelines, and a multidisciplinary approach to reproductive counseling in the context of hereditary cancer risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.